| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Trevena, Inc.$0.01
0 (0%)
C 41Pipeline Score Undervalued Biotech · Clinical
Market Cap
2.13 M
EPS
-55.32
P/E Ratio
-
Value Trade
4.74
SEC Financials
Q3 2024Dilution Risk
R&D Expenses
1.87 M
Total Assets
19.19 M
Total Liabilities
42.50 M
Equity
-23.31 M
D/E Ratio
12,345
-37.86 %
Week
-38.73 %
1 Month
-53.05 %
3 Month
-75.33 %
6 Month
-99.59 %
5 Year
-99.94 %
All Time
Cash Data
Cash Position
13.46 M
Monthly Burn
1.86 M
Runway
0 mo
Burn Trend
StableSEC Filing
Nov 7, 2024
Overview
Volume
427.00
52 Week Range
1.13 - 17.50
% held by Insiders
0 %
% held by Institutions
0.1 %
Enterprise Value
25.67 M
Total Shares
863.79 K
Short %
0.07 %
Float Shares
812.80 K
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C41
Pipeline Score $7M
Pipeline ValueUndervalued
Valuation Signal7
Drugs Scored3.1x
rNPV / MCap Top 58%
Micro Cap (rank 382 of 906)
Percentile RankTrevena, Inc. carries a moderate pipeline score (41/100), with $1.7B risk-adjusted pipeline value, led by TRV130 in Acute Pain (Phase 3), across $51B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRV130 Small molecule | Acute Pain | Phase 3 | NCT02100748 | 49% | $633M | COMPLETED | 1,101 | - | - | Oct 1, 2014 | - | Sep 16, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TRV045 | CNS disorders | — | 2023-11-14 | no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reported Read More | Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and Read More | |
TRV045 | CNS disorders | — | 2023-11-14 | no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reported Read More | Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and Read More | |
TRV045 | CNS disorders | — | 2023-11-14 | no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reported Read More | Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TRVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TRVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How TRVN ranks across every disease it competes inCompetitive Position is a premium feature
See how TRVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial